• LAST PRICE
    1.3100
  • TODAY'S CHANGE (%)
    Trending Down-0.1400 (-9.6552%)
  • Bid / Lots
    1.3300/ 50
  • Ask / Lots
    1.3500/ 1
  • Open / Previous Close
    1.4638 / 1.4500
  • Day Range
    Low 1.3001
    High 1.4900
  • 52 Week Range
    Low 0.6311
    High 7.4889
  • Volume
    88,786
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.45
TimeVolumeVINC
10:06 ET2001.4638
10:09 ET1001.48
10:22 ET1001.4627
10:24 ET1001.49
10:36 ET10001.49
10:42 ET4001.48
10:51 ET108711.46
11:12 ET13001.46
11:16 ET4001.46
11:18 ET16001.46
11:43 ET151911.455
11:45 ET4001.445
12:08 ET2281.45
12:26 ET10001.45
12:48 ET1001.4003
12:50 ET26001.4001
01:00 ET7381.4117
01:02 ET152721.4
01:04 ET70001.42
01:31 ET6401.3641
01:42 ET1001.4
01:45 ET2001.36
01:56 ET2261.3782
02:14 ET14001.37
02:30 ET22211.365
02:32 ET10001.365
02:36 ET19001.33
02:38 ET4001.36
02:39 ET5001.3341
02:54 ET5001.3407
03:03 ET3341.32
03:06 ET1001.3101
03:08 ET10781.3106
03:10 ET2251.33
03:17 ET17801.3125
03:24 ET4951.3001
03:26 ET38141.33
03:28 ET3001.3366
03:53 ET77801.32
03:57 ET4001.32
04:00 ET9701.31
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVINC
Vincerx Pharma Inc
27.8M
-0.5x
---
United StatesAPRE
Aprea Therapeutics Inc
27.8M
-0.1x
---
United StatesADXN
Addex Therapeutics Ltd
25.9M
0.0x
---
United StatesGWLL
Goldenwell Biotech Inc
28.3M
-286.4x
---
United StatesRGLS
Regulus Therapeutics Inc
27.1M
-0.8x
---
United StatesEDSA
Edesa Biotech Inc
28.6M
-1.2x
---
As of 2023-02-05

Company Information

Vincerx Pharma, Inc. is a clinical-stage life sciences company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. Its SMDC platform targets advanced solid tumors with optimized camptothecin, a potent cytotoxin (warhead, payload or toxophore).

Contact Information

Headquarters
260 Sheridan Avenue, Suite 400PALO ALTO, CA, United States 94306
Phone
650-800-6676
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Ahmed Hamdy
President, Chief Operating Officer, Director
Raquel Izumi
Chief Financial Officer
Alexander Seelenberger
Chief Technology Officer
Xiaoming Zhang
General Counsel, Chief Legal Officer
Tom Thomas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$27.8M
Revenue (TTM)
$0.00
Shares Outstanding
21.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.77
Book Value
$4.76
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.